Comparison of one-year costs of Type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 2, 2010, Pages 129-137

  Pscherer, S ^a   Dietrich, E S ^b   Dippel, F W ^c   Neilson, A R ^b  

^a Klinikum Traunstein   (Germany)

^b HealthEcon Ltd   (Switzerland)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Basal insulin; Cost analysis; Insulin detemir; Insulin glargine; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; LEVERMIR; METFORMIN; UNCLASSIFIED DRUG;

ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GERMANY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

EID: 76749113331     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48129     Document Type: Article

References (25)

1. Bierwirth RA, Kohlmann T, Holle R, Landgraf W. Lower treatment costs with insulin glargine compared to insulin detemir as part of a basal-bolus regimen in Type 2 diabetes: results from the LIVE-COM study in Germany. EASD. 2009 (Abstract). LIVE-COM.
2. Claxton K, Schulper M, McCabe C, Briggs A, Akehurst R, Buxton, Brazier J and O'Hagan T. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.HealthEconomics. 2005; 14: 339-347.
3. Dixon S. Evaluating the 'real' cost-effectiveness of health technology: reconciling the public interest with patients' interests Current Medical Research and Opinion. 2007; 23(Suppl): 1-6.
4. Drummond M, Barbieri M, Cook J, Glick H, Lis J, Malik F, et al. Transferability of Economic Evaluations Across Jurisdictions. ISPOR Good Research Practices Task Force Report Value in Health. 2009; 12: 409-418.
5. Evans M, Owens D, Carroll D, Keech M. Cost Savings in Type 2Diabeteswith Insulin Glargine Compared with Insulin Detemir in the UK. Abstract 2016-PO, ADA 69th Scientific Sessions. 2009.
6. Florian Müller GmBh. - the friendly mail-order for diabetics, Wichmannstrasse 4, 22607 Hamburg, www.florian-mueller.de (www.diaexpert.de)
7. Guisasola A, Llorente C, Rubio-Terrés C. Cost analysis of Type 2 diabetes mellitus treatment with glargine insulin or detemir insulin in Spain. Rev Esp Econ Salud. 2007; 6: 304-310.
8. Guisasola A, Llorente C, Rubio-Terrés C. Revisión del estudio "Análisis de costes del tratamiento de la diabetes mellitus de tipo 2 con insulin glargina e insulin detemir en España". Rev Esp Econ Salud. 2008; 7: 150-151.
9. Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T. Kosten für antihyperglykämische Arznei- und Verbrauchsmittel und Therapiezufriedenheit bei Typ-2-Diabetes. Dtsch med Wochenschr. 2009; 134: 1207-1213.
10. Hollander P, Cooper J, Bregnhøj J, Pederson CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with Type 2 diabetes. Clinical Therapeutics. 2008; 30: 1976-1987.
11. Kósa J, Odhiambo R, zRT Sanofi-aventis. Költség-minimalzációs elemzés: ALantus és a detemir bázisinzulinok összehasonlitása a diabetes aktuális terápiás gyakorlatában. Egészség-gazdaságtan Farmakoönómia. 2008; 6: 41-44.
12. LauerTaxe. http://www.lauer-fischer.de/LF/Seiten/Produkte/Lauer- Taxe+online/Lauer-Taxe+online-EN.aspx.
13. Levin PA, Danel A, Bromberger L, Choi JC, Mersey J. Glycemic control and cost-effectiveness following inititation of insulin glargine or detemir in patients with Type 2 diabetes mellitus - an analysis of electronic medical records. Poster ISPOR 11th Annual European Congress, Athens 2008. Value in Health. 2008; 11: PDB 5.
14. Matthaei S, Häring HU. Behandlung des Diabetes mellitus Typ 2. Diabetologie. 2008; 3 (Suppl): 157-161.
15. Minshall ME, Tunis SL, Sauriol L. Cost-effectiveness of insulin glargine compared to insulin detemir for Type 1 and Type 2 diabetesmellitus patients in the Canadian payer setting. Poster ISPOR 11th Annual European Congress, Athens 2008. Value in Health. 2008; 11: A502, PDB22.
16. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
17. Pichón-Riviere A, Caporale JE. Augustovski F, von Schulz-Hausmann C, Gagliardino JJ. Cost comparison of insulin glargine and insulin detemir in Type 2 diabetes mellitus in Argentina: A trial-based probabilistic model. Poster ISPOR 11th Annual European Congress, Athens 2008. Value in Health 11(6).
18. Poole CD. Tetlow T, McEwan P, Holme P, Currie CJ. The prescription cost of managing people with Type 1 and Type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK. A retrospective database analsyis. Current Medical Research and Opinion. 2007; 23(Suppl): 41-48.
19. Roper WesternEurope DiabetesPatient Survey 2004 from GfK Healthcare. www.diabetes-world.net/Portal-f%C3%BCr-Patienten-ininjektion/ Pennadeln--Viele-sparen-am-falschen-Ende.htm?I D = 3367Ypsomed GmbH, Otto-Volger Strasse 7c, 65843 Sulzbach/Taunus, www.ypsomed.de
20. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with Type 2 diabetes. Diabetologica. 2008; 51: 408-416.
21. Schädlich PK, Hagenmeyer EG, Gothe H, Hoer A, Landgraf W, Häussler B. Ressourcenverbrauch und Kosten der Behandlung von Typ-2-Diabetikern mit Insulin glargin oder Insulindetemir: Ergebnisse der LIVE-KK Studie. Diabetologie & Stoffwechsel. 2009; 4: 79 (P 229).
22. Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, et al. German recommendations on health economic evaluation - Third and updated version of the Hanover Consensus. Gesundh ökon Qual manag. 2007; 12: 285-290.
23. Swinnen S, DeVries JH. Higher dose requirements with insulin detemir in Type 2 diabetes - three cases and a review of the literature. Diabetes Research and Clinical Practice. 2009; 84: 24-26.
24. Tetlow AP. The relative cost effectiveness of insulin glargine versus detemir using UK real life data in patients with Type 2 diabetes mellitus. 44th meeting of the European Association of Diabetes Rome, Sept 2008. Abst 1004 www.easd.org.
25. Ypsomed GmbH. Otto-Volger Strasse 7c, 65843 Sulzbach/Taunus, www.ypsomed.de (www.diaexpert.de)